The Allelic Expression of RNA Editing Gene ADARB1 in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization

References

• Eisenberg E, Levanon EY. A-to-I RNA editing – immune protector and transcriptome diversifier. Nat Rev Genet. 2018;19(8):473–490. doi:10.1038/s41576-018-0006-1
   PubMed Web of Science ®Google Scholar
• Fritzell K, Xu LD, Lagergren J, Ohman M. ADARs and editing: the role of A-to-I RNA modification in cancer progression. Semin Cell Dev Biol. 2018;79123–79130. doi:10.1016/j.semcdb.2017.11.018
   Web of Science ®Google Scholar
• Tan MH, Li Q, Shanmugam R, et al. Dynamic landscape and regulation of RNA editing in mammals. Nature. 2017;550(7675):249–254. doi:10.1038/nature24041
   PubMed Web of Science ®Google Scholar
• Chen L, Li Y, Lin CH, et al. Recoding RNA editing of azin1 predisposes to hepatocellular carcinoma. Nat Med. 2013;19(2):209–216. doi:10.1038/nm.3043
   PubMed Web of Science ®Google Scholar
• Hu X, Wan S, Ou Y, et al. RNA over-editing of blcap contributes to hepatocarcinogenesis identified by whole-genome and transcriptome sequencing. Cancer Lett. 2015;357(2):510–519. doi:10.1016/j.canlet.2014.12.006
   PubMed Web of Science ®Google Scholar
• Kang L, Liu X, Gong Z, et al. Genome-wide identification of RNA editing in hepatocellular carcinoma. Genomics. 2015;105(2):76–82. doi:10.1016/j.ygeno.2014.11.005
   PubMed Web of Science ®Google Scholar
• Shi L, Yan P, Liang Y, et al. Circular RNA expression is suppressed by androgen receptor (ar)-regulated adenosine deaminase that acts on RNA (ADAR1) in human hepatocellular carcinoma. Cell Death Dis. 2017;8(11):e3171. doi:10.1038/cddis.2017.556
   PubMed Web of Science ®Google Scholar
• Clutterbuck DR, Leroy A, O’Connell MA, Semple CA. A bioinformatic screen for novel A-I RNA editing sites reveals recoding editing in bc10. Bioinformatics. 2005;21(11):2590–2595. doi:10.1093/bioinformatics/bti411
   PubMed Web of Science ®Google Scholar
• Maas S, Patt S, Schrey M, Rich A. Underediting of glutamate receptor GluR-b mRNA in malignant gliomas. Proc Natl Acad Sci U S A. 2001;98(25):14687–14692. doi:10.1073/pnas.251531398
   PubMed Web of Science ®Google Scholar
• Galeano F, Rossetti C, Tomaselli S, et al. ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14b/Skp2/p21/p27 axis. Oncogene. 2013;32(8):998–1009. doi:10.1038/onc.2012.125
   PubMed Web of Science ®Google Scholar
• Chen YB, Liao XY, Zhang JB, et al. ADAR2 functions as a tumor suppressor via editing IGFBP7 in esophageal squamous cell carcinoma. Int J Oncol. 2017;50(2):622–630. doi:10.3892/ijo.2016.3823
   PubMed Web of Science ®Google Scholar
• Cesarini V, Silvestris DA, Tassinari V, et al. ADAR2/miR-589-3p axis controls glioblastoma cell migration/invasion. Nucleic Acids Res. 2018;46(4):2045–2059. doi:10.1093/nar/gkx1257
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: globocan sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi:10.1002/ijc.31937
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;216018. doi:10.1038/nrdp.2016.18
   Web of Science ®Google Scholar
• Young S, Craig P, Golzarian J. Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques. Eur Radiol. 2019;29(6):3287–3295. doi:10.1007/s00330-018-5782-7
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–1739. doi:10.1016/S0140-6736(02)08649-X
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–1171. doi:10.1053/jhep.2002.33156
   PubMed Web of Science ®Google Scholar
• Liu J, Wang D, Zhou J, et al. N6-methyladenosine reader ythdc2 and eraser fto may determine hepatocellular carcinoma prognoses after transarterial chemoembolization. Arch Toxicol. 2021;95(5):1621–1629. doi:10.1007/s00204-021-03021-3
   PubMed Web of Science ®Google Scholar
• Song Y, Xing H, Zhou L, Zhang N, Yang M. Lncrna h19 modulated by mir-146b-3p/mir-1539-mediated allelic regulation in transarterial chemoembolization of hepatocellular carcinoma. Arch Toxicol. 2021;95(9):3063–3070. doi:10.1007/s00204-021-03119-8
   PubMed Web of Science ®Google Scholar
• Hua H, Zeng J, Xing H, et al. The RNA editing enzyme ADAR modulated by the rs1127317 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma. Life Sci. 2022;296120408. doi:10.1016/j.lfs.2022.120408
   Web of Science ®Google Scholar
• Li W, Wang T, Fu G, et al. The allelic regulation of tumor suppressor ADARB2 in papillary thyroid carcinoma. Endocr Relat Cancer. 2022;30. doi:10.1530/ERC-22-0189
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang T, Zeng J, et al. Integrative functional genomics implicated the key t-/b-cell deficiency regulator rag1 in transarterial chemoembolization of hepatocellular carcinoma. Front Cell Dev Biol. 2021;9720791. doi:10.3389/fcell.2021.720791
   Web of Science ®Google Scholar
• Zhang N, Song Y, Xu Y, et al. Med13l integrates mediator-regulated epigenetic control into lung cancer radiosensitivity. Theranostics. 2020;10(20):9378–9394. doi:10.7150/thno.48247
   PubMed Web of Science ®Google Scholar
• Zheng Y, Lei T, Jin G, et al. Lncpsca in the 8q24.3 risk locus drives gastric cancer through destabilizing ddx5. EMBO Rep. 2021;22(11):e52707. doi:10.15252/embr.202152707
   PubMed Web of Science ®Google Scholar
• Wang C, Zou J, Ma X, Wang E, Peng G. Mechanisms and implications of ADAR-mediated RNA editing in cancer. Cancer Lett. 2017;41127–41134. doi:10.1016/j.canlet.2017.09.036
   Web of Science ®Google Scholar
• Walkley CR, Li JB. Rewriting the transcriptome: adenosine-to-inosine RNA editing by ADARs. Genome Biol. 2017;18(1):205. doi:10.1186/s13059-017-1347-3
   PubMedGoogle Scholar
• Ishizuka JJ, Manguso RT, Cheruiyot CK, et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature. 2019;565(7737):43–48. doi:10.1038/s41586-018-0768-9
   PubMed Web of Science ®Google Scholar
• Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018;37(1):110. doi:10.1186/s13046-018-0777-4
   PubMed Web of Science ®Google Scholar
• Li Z, Wu X, Zhao Y, et al. Clinical benefit of neoadjuvant anti-pd-1/pd-l1 utilization among different tumors. MedComm. 2021;2(1):60–68. doi:10.1002/mco2.61
   PubMedGoogle Scholar
• Chan TH, Lin CH, Qi L, et al. A disrupted RNA editing balance mediated by ADARs (adenosine deaminases that act on RNA) in human hepatocellular carcinoma. Gut. 2014;63(5):832–843. doi:10.1136/gutjnl-2012-304037
   PubMed Web of Science ®Google Scholar
• Song Y, An O, Ren X, et al. RNA editing mediates the functional switch of COPA in a novel mechanism of hepatocarcinogenesis. J Hepatol. 2021;74(1):135–147. doi:10.1016/j.jhep.2020.07.021
   PubMed Web of Science ®Google Scholar
• Liu WH, Chen CH, Yeh KH, et al. ADAR2-mediated editing of miR-214 and miR-122 precursor and antisense RNA transcripts in liver cancers. PLoS One. 2013;8(12):e81922. doi:10.1371/journal.pone.0081922
   PubMed Web of Science ®Google Scholar
• Leone P, Solimando AG, Fasano R, et al. The evolving role of immune checkpoint inhibitors in hepatocellular carcinoma treatment. Vaccines. 2021;9(5):532. doi:10.3390/vaccines9050532
   Web of Science ®Google Scholar